It targets two important hormone pathwaysGLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptorsenhancing appetite regulation, glucose control, and metabolism more powerfully than previous treatments
No opinion given in the material constitutes a recommendation by EBC or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person
Appetite Suppression and Fueling Strategies One of the most significant ways GLP-1 therapy affects exercise performance is through appetite control
Of adults receiving tirzepatide who had no or minimal depression symptoms at baseline, 79.4% remained in that category through the end of safety follow-up, 17% reported mild depression symptoms, 2.9% had moderate symptoms, 0.7% reported moderately severe symptoms and 0.1% had severe symptoms
Clinical trials show that participants can lose an average of 15 to 20 percent of their body weight over 72 weeks
